{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:30:58Z","timestamp":1792481458669,"version":"4.5.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119118","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:08:00Z","timestamp":1782850080000},"page":"119118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Advances in selective inhibitors targeting the BD1 and BD2 domains of BET proteins"],"prefix":"10.1016","volume":"317","author":[{"given":"Jia-Yao","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-Wei","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Lin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3820-3693","authenticated-orcid":false,"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119118_bib1","first-page":"10","article-title":"Epigenetic modification and cancer","volume":"18","author":"Lu","year":"2006","journal-title":"Chin. Bull. Life Sci."},{"key":"10.1016\/j.ejmech.2026.119118_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119118_bib3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fonc.2015.00108","article-title":"The role of histone acetyltransferases in normal and malignant hematopoiesis","volume":"5","author":"Sun","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119118_bib4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2026.119118_bib5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0959-437X(03)00015-7","article-title":"Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression","volume":"13","author":"Yang","year":"2003","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.ejmech.2026.119118_bib6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/ng1966","article-title":"Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome","volume":"39","author":"Heintzman","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2026.119118_bib7","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ng.154","article-title":"Combinatorial patterns of histone acetylations and methylations in the human genome","volume":"40","author":"Wang","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2026.119118_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2023.168376","article-title":"Distinct histone H3 lysine 27 modifications dictate different outcomes of gene transcription","volume":"436","author":"Konuma","year":"2024","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.119118_bib9","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2741\/4847","article-title":"Epigenetic alterations in cancer","volume":"25","author":"Ilango","year":"2020","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"10.1016\/j.ejmech.2026.119118_bib10","first-page":"1253","article-title":"Epigenetic related drugs in cancer therapy","volume":"40","author":"Wang","year":"2018","journal-title":"Chinese J. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119118_bib11","first-page":"1008","article-title":"You bet-cha: a novel family of transcriptional regulators","volume":"6","author":"Florence","year":"2001","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejmech.2026.119118_bib12","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1128\/.20.17.6537-6549.2000","article-title":"A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G(2)-to-M transition","volume":"20","author":"Dey","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119118_bib13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cell.2012.02.013","article-title":"Histone recognition and large-scale structural analysis of the human bromodomain family","volume":"149","author":"Filippakopoulos","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119118_bib14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccr.2014.01.028","article-title":"Disrupting the interaction of BRD4 with diacetylated twist suppresses tumorigenesis in basal-like breast cancer","volume":"25","author":"Shi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.119118_bib15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/20974","article-title":"Structure and ligand of a histone acetyltransferase bromodomain","volume":"399","author":"Dhalluin","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119118_bib16","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1126\/science.288.5470.1422","article-title":"Structure and function of a human TAFII250 double bromodomain module","volume":"288","author":"Jacobson","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119118_bib17","first-page":"656","article-title":"Research progress of bromodomain-containing protein 4 small-molecule inhibitors and its degraders","volume":"44","author":"Feng","year":"2020","journal-title":"Prog. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2026.119118_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.005","article-title":"Bromodomains: structure, function and pharmacology of inhibition","volume":"106","author":"Ferri","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119118_bib19","doi-asserted-by":"crossref","first-page":"9045","DOI":"10.1021\/acs.jmedchem.0c00614","article-title":"GSK789: a selective inhibitor of the first bromodomains (BD1) of the bromo and extra terminal domain (BET) proteins","volume":"63","author":"Watson","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib20","doi-asserted-by":"crossref","first-page":"15728","DOI":"10.1021\/acs.jmedchem.3c00906","article-title":"Structure-guided design of a domain-selective bromodomain and extra terminal N-Terminal bromodomain chemical probe","volume":"66","author":"Bradley","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib21","doi-asserted-by":"crossref","first-page":"11625","DOI":"10.1021\/acs.chemrev.5b00205","article-title":"Discovery of chemical inhibitors of human bromodomains","volume":"115","author":"Zhang","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.119118_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13855","article-title":"A bromodomain-DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT","volume":"7","author":"Miller","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119118_bib23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41594-020-0394-8","article-title":"Roles of the BRD4 short isoform in phase separation and active gene transcription","volume":"27","author":"Han","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.119118_bib24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.molcel.2012.12.006","article-title":"Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting","volume":"49","author":"Wu","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.119118_bib25","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1021\/acs.biochem.2c00157","article-title":"Alternative mechanisms for DNA engagement by BET bromodomain-containing proteins","volume":"61","author":"Kalra","year":"2022","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2026.119118_bib26","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.18632\/oncotarget.6275","article-title":"Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2026.119118_bib27","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.1158\/0008-5472.CAN-16-0559","article-title":"BRD4 regulates breast cancer dissemination through Jagged1\/Notch1 signaling","volume":"76","author":"Andrieu","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119118_bib28","first-page":"1365","article-title":"Research advances in the mechanisms of BRD4 and its inhibitors in hematologic malignancies","volume":"29","author":"Gao","year":"2021","journal-title":"J. Exp. Hematol."},{"key":"10.1016\/j.ejmech.2026.119118_bib29","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1126\/science.aao2793","article-title":"SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis","volume":"360","author":"Muhar","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119118_bib30","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.bbrc.2012.07.149","article-title":"Brd2 is required for cell cycle exit and neuronal differentiation through the E2F1 pathway in mouse neuroepithelial cells","volume":"425","author":"Tsume","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2026.119118_bib31","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.stemcr.2015.01.012","article-title":"The BET family member BRD4 interacts with OCT4 and regulates pluripotency gene expression","volume":"4","author":"Wu","year":"2015","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.ejmech.2026.119118_bib32","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1158\/0008-5472.CAN-18-0484","article-title":"EWS\/ETS-Driven ewing sarcoma requires BET bromodomain proteins","volume":"78","author":"Gollavilli","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119118_bib33","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","article-title":"The mechanisms behind the therapeutic activity of BET bromodomain inhibition","volume":"54","author":"Shi","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.119118_bib34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/biomedicines6010016","article-title":"BET family protein BRD4: an emerging actor in NF\u03baB signaling in inflammation and cancer","volume":"6","author":"Hajmirza","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2026.119118_bib35","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026674","article-title":"Targeting cancer cells with BET Bromodomain inhibitors","volume":"7","author":"Xu","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejmech.2026.119118_bib36","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119118_bib37","first-page":"290","article-title":"First light before dawn: preliminary exploration and challenges of OTX015\/MK-8628 in the treatment of NUT midline carcinoma","volume":"24","author":"Wei","year":"2024","journal-title":"J. Evid. Base Med."},{"key":"10.1016\/j.ejmech.2026.119118_bib38","doi-asserted-by":"crossref","first-page":"10464","DOI":"10.1021\/acs.jmedchem.4c00959","article-title":"Structure- and property-based optimization of efficient pan-bromodomain and extra terminal inhibitors to identify oral and intravenous candidate I-BET787","volume":"67","author":"Hirst","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107479","article-title":"Make your best BET: the emerging role of BET inhibitor treatment in malignant tumors","volume":"208","author":"Bechter","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.119118_bib40","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1021\/acs.jmedchem.6b01761","article-title":"Drug discovery targeting bromodomain-containing protein 4","volume":"60","author":"Liu","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib41","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.chembiol.2014.05.009","article-title":"Selective chemical modulation of gene transcription favors oligodendrocyte lineage progression","volume":"21","author":"Gacias","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119118_bib42","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.chembiol.2005.10.014","article-title":"Target structure-based discovery of small molecules that block human p53 and CREB binding protein association","volume":"13","author":"Sachchidanand","year":"2006","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119118_bib43","doi-asserted-by":"crossref","first-page":"9020","DOI":"10.1021\/acs.jmedchem.0c00566","article-title":"Structure-based design of a bromodomain and extraterminal domain (BET) inhibitor selective for the N-Terminal bromodomains that retains an anti-inflammatory and antiproliferative phenotype","volume":"63","author":"Wellaway","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117752","article-title":"Discovery of indole-2-one derivatives as BRD4 (BD1) selective inhibitors","volume":"106","author":"Qiao","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib45","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.bmc.2019.03.037","article-title":"Binding pocket-based design, synthesis and biological evaluation of novel selective BRD4-BD1 inhibitors","volume":"27","author":"Ma","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib46","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s00044-021-02737-2","article-title":"Design, synthesis, biological evaluation, and molecular docking of 1,7-dibenzyl-substituted theophylline derivatives as novel BRD4-BD1-selective inhibitors","volume":"30","author":"Chang","year":"2021","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2026.119118_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116592","article-title":"Design, synthesis and anticancer evaluation of 3-methyl-1H-indazole derivatives as novel selective bromodomain-containing protein 4 inhibitors","volume":"55","author":"Dong","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12342-2","article-title":"BRD4 regulates adiponectin gene induction by recruiting the P-TEFb complex to the transcribed region of the gene","volume":"7","author":"Sakurai","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119118_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117272","article-title":"Design, synthesis, and antitumor evaluation of triazolopyridine derivatives as novel inhibitors for BRD4","volume":"285","author":"Liu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105917","article-title":"Design, synthesis, and anticancer evaluation of ammosamide B with pyrroloquinoline derivatives as novel BRD4 inhibitors","volume":"127","author":"Li","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib51","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.1021\/acs.jmedchem.4c03069","article-title":"Multi-water bridges enable design of BET BD1-Selective inhibitors for pancreatic cancer therapy","volume":"68","author":"Chen","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib52","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2122506119","article-title":"Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections","volume":"119","author":"Modukuri","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.119118_bib53","doi-asserted-by":"crossref","first-page":"9316","DOI":"10.1021\/acs.jmedchem.8b01248","article-title":"Molecular basis for the N-Terminal bromodomain-and-extra-terminal-family selectivity of a dual kinase-bromodomain inhibitor","volume":"61","author":"Divakaran","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib54","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1021\/acs.jmedchem.1c01779","article-title":"A structure-based design approach for generating high affinity BRD4 D1-Selective chemical probes","volume":"65","author":"Cui","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib55","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1021\/acs.jmedchem.0c00035","article-title":"Discovery of orally bioavailable chromone derivatives as potent and selective BRD4 inhibitors: Scaffold hopping, optimization, and pharmacological evaluation","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib56","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1158\/1078-0432.CCR-19-0578","article-title":"First-in-Human study of mivebresib (ABBV-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed\/refractory solid tumors","volume":"25","author":"Piha-Paul","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119118_bib57","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1021\/acs.jmedchem.0c00628","article-title":"Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET bromodomain inhibitor with selectivity for the second bromodomain","volume":"63","author":"Sheppard","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib58","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41586-020-1930-8","article-title":"Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer","volume":"578","author":"Faivre","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119118_bib59","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2025018695","article-title":"Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy in patients with myelofibrosis","author":"Mascarenhas","year":"2026","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejmech.2026.119118_bib60","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1021\/acs.jmedchem.7b01666","article-title":"Discovery of tetrahydroquinoxalines as bromodomain and extra-terminal domain (BET) inhibitors with selectivity for the second bromodomain","volume":"61","author":"Law","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib61","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1124\/mol.117.110379","article-title":"RVX-297, a BET bromodomain inhibitor, has therapeutic effects in preclinical models of acute inflammation and autoimmune disease","volume":"92","author":"Jahagirdar","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119118_bib62","doi-asserted-by":"crossref","first-page":"9093","DOI":"10.1021\/acs.jmedchem.0c00796","article-title":"The optimization of a novel, weak bromo and extra terminal domain (BET) bromodomain fragment ligand to a potent and selective second bromodomain (BD2) inhibitor","volume":"63","author":"Seal","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib63","doi-asserted-by":"crossref","DOI":"10.1007\/s12039-025-02386-7","article-title":"Discovery of a novel lead compound targeting BRD4 BD2 with a di-phenyl ether fragment: synthesis, molecular docking and drug-likeness studies","volume":"137","author":"Zhang","year":"2025","journal-title":"J. Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.119118_bib64","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/14756366.2021.1906663","article-title":"Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor","volume":"36","author":"Li","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib65","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1021\/acs.jmedchem.2c00100","article-title":"Structure-based discovery and optimization of Furo[3,2-c]pyridin-4(5H)-one derivatives as potent and second bromodomain (BD2)-selective bromo and extra terminal domain (BET) inhibitors","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib66","doi-asserted-by":"crossref","first-page":"21577","DOI":"10.1021\/acs.jmedchem.4c02516","article-title":"Discovery of the first BRD4 second bromodomain (BD2)-selective inhibitors","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib67","doi-asserted-by":"crossref","first-page":"10806","DOI":"10.1021\/acs.jmedchem.1c00412","article-title":"Discovery of a highly selective BET BD2 inhibitor from a DNA-encoded library technology screening hit","volume":"264","author":"Rianjongdee","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib68","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.drudis.2011.06.001","article-title":"Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity","volume":"16","author":"Young","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119118_bib69","doi-asserted-by":"crossref","first-page":"10824","DOI":"10.1021\/acs.jmedchem.3c01028","article-title":"Discovery of a bromodomain and extra terminal domain (BET) inhibitor with the selectivity for the second bromodomain (BD2) and the capacity for the treatment of inflammatory diseases","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib70","doi-asserted-by":"crossref","first-page":"9070","DOI":"10.1021\/acs.jmedchem.0c00605","article-title":"Design and synthesis of a highly selective and in vivo-capable inhibitor of the second bromodomain of the bromodomain and extra terminal domain family of proteins","volume":"63","author":"Preston","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib71","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2021102118","article-title":"Discovery and characterization of bromodomain 2-specific inhibitors of BRDT","volume":"118","author":"Yu","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2026.119118_bib72","article-title":"1,4-Dihydropyridinebutyrolactone-derived ring-opened ester and amide analogs targeting BET bromodomains","volume":"355","author":"Jiang","year":"2022","journal-title":"Arch. Pharm. (Weinh.)"},{"key":"10.1016\/j.ejmech.2026.119118_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117504","article-title":"Macrocyclic dihydropyridine analogs as pan-BET BD2-preferred inhibitors","volume":"290","author":"Jiang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib74","first-page":"682","article-title":"Advances in research on selective BRD4 BD1\/BRD4 BD2 inhibitors","volume":"47","author":"Huang","year":"2023","journal-title":"Prog. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2026.119118_bib75","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.119118_bib76","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119118_bib77","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119118_bib78","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119118_bib79","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2026.119118_bib80","doi-asserted-by":"crossref","first-page":"26663","DOI":"10.1002\/anie.202108848","article-title":"Phenyl-glutarimides: alternative cereblon binders for the design of PROTACs","volume":"60","author":"Min","year":"2021","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2026.119118_bib81","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1021\/acs.jmedchem.4c02709","article-title":"Evaluation of cereblon-directing warheads for the development of orally bioavailable PROTACs","volume":"68","author":"Actis","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib82","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1021\/acschembio.5c00343","article-title":"Temporal and spatial characterization of CUL3KLHL20-Driven targeted degradation of BET family BRD proteins by the macrocycle-based degrader BTR2004","volume":"20","author":"Fechtmeyer","year":"2025","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119118_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118491","article-title":"Photocleavable PROTACs as tools for dynamic regulation of protein function","volume":"133","author":"Xu","year":"2026","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118667","article-title":"Design and evaluation of selective BET PROTACs with potent antitumor efficacy and safety against acute myeloid leukemia","volume":"308","author":"Wei","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119118_bib85","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.molcel.2017.06.004","article-title":"BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment","volume":"67","author":"Winter","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.119118_bib86","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119118_bib87","first-page":"177","article-title":"Advance in anti-tumor mechanism study of bromodomain-containing protein 4 inhibitors","volume":"2","author":"Wu","year":"2019","journal-title":"Antitumor Pharm."},{"key":"10.1016\/j.ejmech.2026.119118_bib88","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1038\/s41401-024-01318-4","article-title":"ABBV-744 alleviates LPS-induced neuroinflammation via regulation of BATF2-IRF4-STAT1\/3\/5 axis","volume":"45","author":"Wang","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2026.119118_bib89","volume":"WO 2022116968 A1","author":"Zhu","year":"2022"},{"key":"10.1016\/j.ejmech.2026.119118_bib90","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature14888","article-title":"BET inhibitor resistance emerges from leukaemia stem cells","volume":"525","author":"Fong","year":"2015","journal-title":"Nature"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:07:37Z","timestamp":1787040457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426005635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":90,"alternative-id":["S0223523426005635"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119118","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in selective inhibitors targeting the BD1 and BD2 domains of BET proteins","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119118","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119118"}}